Vaxcyte completes enrollment for two Phase 3 trials of VAX-31 vaccine

March 23, 2026 8:30 AM

Vaxcyte Inc. (NASDAQ: PCVX) announced completion of enrollment in two Phase 3 clinical trials evaluating its VAX-31 pneumococcal conjugate vaccine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found